Literature DB >> 3609072

Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.

A Celardo, G L Traina, M Arboix, A Puigdemont, M Bonati.   

Abstract

The pharmacokinetic and pharmacodynamic profiles of atenolol were studied in adult male rabbits on continuous peritoneal dialysis given 3 mg/kg i.v. before and during renal failure. The average terminal elimination half-life for the drug was 2.5 h calculated from blood, dialysate or urinary data. This value increased about nine times in anuric conditions. Although atenolol was eliminated in the peritoneal fluid, the amount excreted was relatively low both in normal conditions and renal failure, respectively 0.6 and 7% of the administered dose. The pharmacokinetic model was extended by an "effect compartment", which has no influence on the predetermined mass of drug in the body, to analyse the relationship between heart rate fall and changes in atenolol blood concentrations. After drug administration, heart rate fell rapidly about 90 beats in both states. The mean equilibration half-time of atenolol effect and blood concentrations was 0.7 and 1.5 h in normal and pathological states, respectively. The mean blood concentration required to produce 50% of heart rate fall was similar in both conditions, 0.23 mg/l. The nine-fold decrease of atenolol elimination in anuria was in good agreement with the increase in duration of the drug's effect, and was suitably described by the "effect model".

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609072     DOI: 10.1007/BF03189860

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  Metabolism of atenolol in man.

Authors:  P R Reeves; J McAinsh; D A McIntosh; M J Winrow
Journal:  Xenobiotica       Date:  1978-05       Impact factor: 1.908

2.  Continuous ambulatory peritoneal dialysis: a new era in the treatment of chronic renal failure.

Authors:  D G Oreopoulos; M Robson; B Faller; R Ogilvie; A Rapoport; G A deVeber
Journal:  Clin Nephrol       Date:  1979-03       Impact factor: 0.975

3.  NL-FIT: a microcomputer program for non-linear fitting.

Authors:  G S Landriani; V Guardabasso; M Rocchetti
Journal:  Comput Programs Biomed       Date:  1983 Feb-Apr

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Experimental model for studies of continuous peritoneal'dialysis in uremic rabbits.

Authors:  L Gotloib; P Crassweller; H Rodella; D G Oreopoulos; G Zellerman; R Ogilvie; H Husdan; L Brandes; S Vas
Journal:  Nephron       Date:  1982       Impact factor: 2.847

6.  Atenolol determination by high-performance liquid chromatography and fluorescence detection.

Authors:  Y G Yee; P Rubin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-04-01

7.  Red cell survival and red cell enzymes in patients on continuous peritoneal dialysis (CAPD).

Authors:  J E Hefti; A Blumberg; H R Marti
Journal:  Clin Nephrol       Date:  1983-05       Impact factor: 0.975

8.  Atenolol kinetics in renal failure.

Authors:  J McAinsh; B F Holmes; S Smith; D Hood; D Warren
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis: the role of erythropoietin.

Authors:  A R Zappacosta; J Caro; A Erslev
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

View more
  1 in total

1.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.